The growth and dependence of Prostate Cancer (PCa) on androgen stimulation led to the
use of castration to reduce circulating levels of androgens and anti-androgens to directly …

Prostate cancer is the most common cancer in European men and the second leading cause
of death [1]. For patients who relapse after treatment of organ-confined disease or those who …

Opinion statement Recent results of phase III randomized studies confirm that targeting the
androgen receptor (AR)—through inhibition of androgen synthesis or through AR targeting …

The FDA approvals of enzalutamide and abiraterone have rapidly changed the clinical
landscape of prostate cancer treatment. Both drugs were designed to further suppress …

Abiraterone acetate is a novel CYP17A1 inhibitor demonstrated to prolong survival in
castration-resistant prostate cancer (CRPC). This review explores key stages in the almost …

Abiraterone acetate is the first second-line hormonal agent proven to improve survival in
metastatic castration-resistant prostate cancer. It selectively inhibits cytochrome P450 17 …

Reactivated androgen receptor (AR) signaling drives castration‐resistant prostate cancer
(CRPC). The novel AR targeting drugs abiraterone and enzalutamide have improved …

After initial response to androgen receptor (AR) targeting drugs abiraterone or
enzalutamide, most patients develop progressive disease and therefore, castration resistant …

Significant progress has been made in the understanding of the underlying cancer biology
of castration‐resistant prostate cancer (CRPC) with the androgen receptor (AR) signalling …

Background: Despite the progress and innovation in chemo-and immunotherapies,
androgen deprivation therapy remains the standard treatment of metastatic prostate cancer …